Suppr超能文献

活细胞中 RAS 蛋白相互作用分析揭示了一种通过膜靶向 RAS 结合物耗尽 pan-RAS 的机制。

Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders.

机构信息

Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037.

Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.

出版信息

Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12121-12130. doi: 10.1073/pnas.2000848117. Epub 2020 May 18.

Abstract

HRAS, NRAS, and KRAS4A/KRAS4B comprise the RAS family of small GTPases that regulate signaling pathways controlling cell proliferation, differentiation, and survival. RAS pathway abnormalities cause developmental disorders and cancers. We found that KRAS4B colocalizes on the cell membrane with other RAS isoforms and a subset of prenylated small GTPase family members using a live-cell quantitative split luciferase complementation assay. RAS protein coclustering is mainly mediated by membrane association-facilitated interactions (MAFIs). Using the RAS-RBD (CRAF RAS binding domain) interaction as a model system, we showed that MAFI alone is not sufficient to induce RBD-mediated RAS inhibition. Surprisingly, we discovered that high-affinity membrane-targeted RAS binding proteins inhibit RAS activity and deplete RAS proteins through an autophagosome-lysosome-mediated degradation pathway. Our results provide a mechanism for regulating RAS activity and protein levels, a more detailed understanding of which should lead to therapeutic strategies for inhibiting and depleting oncogenic RAS proteins.

摘要

HRAS、NRAS 和 KRAS4A/KRAS4B 构成了 RAS 家族的小 GTPases,可调节控制细胞增殖、分化和存活的信号通路。RAS 通路异常会导致发育障碍和癌症。我们发现,使用活细胞定量分裂萤光素酶互补测定法,KRAS4B 与其他 RAS 同工型和一部分已酰化的小 GTPase 家族成员在细胞膜上共定位。RAS 蛋白共聚类主要由膜结合促进相互作用(MAFI)介导。我们以 RAS-RBD(CRAF RAS 结合结构域)相互作用作为模型系统,表明 MAFI 本身不足以诱导 RBD 介导的 RAS 抑制。令人惊讶的是,我们发现高亲和力的靶向细胞膜的 RAS 结合蛋白通过自噬体-溶酶体介导的降解途径抑制 RAS 活性并耗尽 RAS 蛋白。我们的结果提供了一种调节 RAS 活性和蛋白水平的机制,更详细地了解这一点应该会导致抑制和耗尽致癌性 RAS 蛋白的治疗策略。

相似文献

1
Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders.
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12121-12130. doi: 10.1073/pnas.2000848117. Epub 2020 May 18.
2
Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Cancer Res. 2018 Feb 1;78(3):593-602. doi: 10.1158/0008-5472.CAN-17-2727. Epub 2017 Dec 22.
3
Differential functions of the KRAS splice variants.
Biochem Soc Trans. 2023 Jun 28;51(3):1191-1199. doi: 10.1042/BST20221347.
4
Origin and Evolution of RAS Membrane Targeting.
Oncogene. 2023 May;42(21):1741-1750. doi: 10.1038/s41388-023-02672-z. Epub 2023 Apr 8.
6
Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids.
J Biol Chem. 2020 Apr 3;295(14):4526-4540. doi: 10.1074/jbc.RA119.011025. Epub 2020 Feb 20.
7
Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt B):2304-2314. doi: 10.1016/j.bbadis.2017.10.032. Epub 2017 Oct 31.
8
Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Oncogene. 2023 Apr;42(15):1224-1232. doi: 10.1038/s41388-023-02638-1. Epub 2023 Mar 2.
9
Conserved allosteric perturbation of the GTPase domains by region 1 of Ras hypervariable regions.
Biophys J. 2024 Apr 2;123(7):839-846. doi: 10.1016/j.bpj.2024.02.022. Epub 2024 Feb 27.
10
A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners.
J Biol Chem. 2021 Jan-Jun;296:100626. doi: 10.1016/j.jbc.2021.100626. Epub 2021 Apr 28.

引用本文的文献

1
Mathematical modeling suggests 14-3-3 proteins modulate RAF paradoxical activation.
PLoS Comput Biol. 2025 Aug 1;21(8):e1013297. doi: 10.1371/journal.pcbi.1013297. eCollection 2025 Aug.
2
Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3.
bioRxiv. 2024 Dec 20:2024.12.18.628944. doi: 10.1101/2024.12.18.628944.
3
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution.
Nat Biotechnol. 2024 Dec;42(12):1888-1898. doi: 10.1038/s41587-023-02107-w. Epub 2024 Jan 25.
4
KRAS is vulnerable to reversible switch-II pocket engagement in cells.
Nat Chem Biol. 2022 Jun;18(6):596-604. doi: 10.1038/s41589-022-00985-w. Epub 2022 Mar 21.
5
Equilibria between conformational states of the Ras oncogene protein revealed by high pressure crystallography.
Chem Sci. 2022 Jan 13;13(7):2001-2010. doi: 10.1039/d1sc05488k. eCollection 2022 Feb 16.
6
Protease-controlled secretion and display of intercellular signals.
Nat Commun. 2022 Feb 17;13(1):912. doi: 10.1038/s41467-022-28623-y.
8
Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma.
J Biol Chem. 2021 Dec;297(6):101353. doi: 10.1016/j.jbc.2021.101353. Epub 2021 Oct 27.
9
Ras isoform-specific expression, chromatin accessibility, and signaling.
Biophys Rev. 2021 Jul 31;13(4):489-505. doi: 10.1007/s12551-021-00817-6. eCollection 2021 Aug.
10
RAS Nanoclusters: Dynamic Signaling Platforms Amenable to Therapeutic Intervention.
Biomolecules. 2021 Mar 3;11(3):377. doi: 10.3390/biom11030377.

本文引用的文献

1
DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters.
Cell Rep. 2019 Dec 10;29(11):3448-3459.e6. doi: 10.1016/j.celrep.2019.11.045.
2
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
4
A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.
Mol Cancer Ther. 2018 Aug;17(8):1773-1780. doi: 10.1158/1535-7163.MCT-17-0645. Epub 2018 May 2.
5
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006.
6
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.
7
K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions.
Biophys J. 2018 Jan 9;114(1):137-145. doi: 10.1016/j.bpj.2017.10.042.
8
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Cell Chem Biol. 2017 Aug 17;24(8):1005-1016.e3. doi: 10.1016/j.chembiol.2017.06.017. Epub 2017 Aug 3.
9
An engineered protein antagonist of K-Ras/B-Raf interaction.
Sci Rep. 2017 Jul 19;7(1):5831. doi: 10.1038/s41598-017-05889-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验